Trial · NCT06350006
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor
NCT06350006, Phase 1, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor. Trials, record NCT06350006. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06350006
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor
- NCT number
- NCT06350006
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 924 participants, estimated
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Conditions
- CLDN18.2-positive Advanced Solid Tumor
- Interventions
- SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab
- First posted
- 2024-04-05
- Last updated
- 2025-12-31
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of AE | Up to follow-up period, approximately 24 months | Phase 1b |
| Primary | Dose Limiting Toxicity (DLT) | approximately 24 months | Phase 1b |
| Primary | Maximal Tolerable Dose (MTD) | approximately 24 months | Phase 1b |
| Primary | Phase III Recommended Dose (RP3D) | approximately 24 months | Phase 1b |
| Primary | Progression-free survival (PFS) assessed by blind Independent Center Review (BICR) based on RECIST 1.1 criteria | approximately 36 months | Phase 3 |
| Secondary | SHR-A1904 toxin binding antibody | approximately 24 months | Phase 1b |
| Secondary | SHR-A1904 Total antibody | approximately 24 months | Phase 1b |
| Secondary | Immunogenicity indicators of SHR-A1904: drug resistant antibody (ADA) and neutralizing antibody (NAb) | approximately 24 months | Phase 1b |
| Secondary | Expression level of CLDN18.2 in tumor tissues | approximately 24 months | Phase 1b |
| Secondary | Overall survival (OS) | approximately 36 months | Phase 3 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06350006
GET https://conductscience.org/api/trials/v1/NCT06350006/registered